Our portfolio includes more than 24 specialized products aimed at providing innovative treatments for unmet medical needs worldwide.
The list below includes our products marketed in the United States. Many of these, as well as other Sanofi Genzyme products, are also approved and marketed in other parts of the world.
Contact Sanofi Genzyme in your region if you are outside the U.S. and want to learn about products available in your area.
Aldurazyme® (laronidase)
Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
AUBAGIO® (teriflunomide)
Cablivi® (caplacizumab-yhdp)
Cerdelga® (eliglustat) capsules
Cerezyme® (imiglucerase for injection)
Clolar® (clofarabine injection)
Dupixent® (dupilumab) injection
ELITEK® (rasburicase)
Eloctate® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
ELOXATIN® (oxaliplatin)
Fabrazyme® (agalsidase beta)
JEVTANA® (cabazitaxel)
KEVZARA® (sarilumab) injection
LIBTAYO® (cemiplimab-rwlc) injection
Lumizyme® (alglucosidase alfa)
Sarclisa® (isatuxamab-irfc) injection for Intravenous Use
TAXOTERE® (docetaxel) injection
ZALTRAP® (ziv-aflibercept) injection for intravenous infusion
What’s in the pipeline?
New product candidates and advances in technology are featured in our product pipeline, which highlights our key research from early stage programs to phase 3 clinical trials.